SCHEMBL365523

SCHEMBL365523

CCS(=O)(=O)NC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 4/20 0.59
MCL1 Q07820 4/20 0.59
MMP1 P03956 2/20 0.56
HDAC3 O15379 1/20 0.56
HPGD P15428 2/20 0.53
MAPK14 Q16539 2/20 0.52
PGR P06401 1/20 0.51
MMP2 P08253 4/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
ERCC5 P28715 1/20 0.50
FEN1 P39748 1/20 0.50
TSHR P16473 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
MMP13 P45452 2/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680592 0.88 MMP13 (0.61) BCL2L1MCL1HPGDMAPK14MMP2
SCHEMBL363932 0.86 BCL2L1 (0.56) BCL2L1MCL1MMP1HDAC3HPGD
SCHEMBL16320154 0.86 MMP1 (0.57) BCL2L1MCL1MMP1HPGDMAPK14
SCHEMBL365989 0.85 BCL2L1 (0.50) BCL2L1MCL1MMP1HDAC3PGR
SCHEMBL1370670 0.85 LMNA (0.54) HDAC3HPGDCA12CA1CA9
SCHEMBL7983736 0.82 CA1 (0.62) HDAC3SMN1; SMN2CA1CA2LMNA
SCHEMBL7985089 0.81 PLK1 (0.65) HPGDSMN1; SMN2LMNAPARP10
SCHEMBL13754242 0.79 HPGD (0.66) MMP1HDAC3HPGDMAPK14PGR
SCHEMBL30163942 0.78 KMT2A (0.53) MCL1HPGDHTTSMN1; SMN2LMNA
SCHEMBL7973513 0.78 MMP1 (0.61) MMP1HTTSMN1; SMN2TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A BCL2L1 3284/4885MCL1 2739/4885MMP1 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.